EHA 2022 | Combination therapies and their role in the ALL treatment landscape
Nicholas Short
• 12 Jun 2022
In this video, Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the sequencing of therapies for acute lymphoblastic leukemia (ALL), highlighting the important role of monoclonal antibodies and combination approaches, as well as future directions in the field. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
N.J.S. reports receiving research grants from Takeda Oncology, Astellas Pharma Inc., Stemline Therapeutics, Inc, and Xencor and has received honoraria from Amgen, Jazz Pharmaceuticals, Astellas Pharmac, Inc., Novartis and Pfizer.
